Transforming Oncology
Advancing GBM treatment through pioneering research and transformative therapies for improved patient outcomes.
CNS Pharmaceuticals Recently Announced it has Expanded its Pipeline with In-License of Late Stage, Novel Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Company Hosted Webcast July 30th
Our Focus
Our primary focus is on glioma, specifically glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. With a deep understanding of the disease and a commitment to innovation, we aim to change the prognosis for patients suffering from this devastating condition. Discover more about glioblastoma multiforme and our approach to tackling it.
Learn More about Our FocusFor Patients
CNS Pharmaceuticals is dedicated to supporting patients and their families throughout their cancer journey. Our 'For Patients' page offers valuable resources, including information about our clinical trials, treatment options, and support networks. Visit our 'For Patients' page to learn more and find the help you need.
Learn More about For PatientsOur Pipeline
Our primary focus is on glioblastoma multiforme, an aggressive and currently incurable form of brain cancer. With a deep understanding of the disease and a commitment to innovation, we aim to change the prognosis for patients suffering from this devastating condition. Discover more about glioblastoma multiforme and our approach to tackling it.
Learn More about Our PipelineLatest News
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11 2024
Read More of CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11 2024CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM WHO Grade IV After Failure of Standard First Line Therapy
Read More of CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM WHO Grade IV After Failure of Standard First Line TherapyCNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro Oncology SNO 2024
Read More of CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro Oncology SNO 2024Investor Relations
Explore our financial data and market performance. Get a clear picture of our strategic outlook.
Presentations
Access our comprehensive publications and presentations page for information on our research programs.
Email Alerts
Get timely updates on our latest developments. Subscribe to email alerts for new press releases, events, and filings.
Pipeline
Track our ongoing research and development projects. Monitor the progress and future of our drug programs.